The Next Breakthrough in Schizophrenia Could be a Digital Therapeutic
A phase 3 trial has demonstrated that CT-155, a smartphone app, can reduce the negative symptoms of schizophrenia.
CT-155 integrates psychosocial interventions delivered using an adaptive goal-setting technique and was developed by Boehringer Ingelheim and Click Therapeutics.
A prescription digital therapy has shown good tolerability and no significant adverse events when administered with an antipsychotic treatment, according to data presented at the 38th Annual European College of Neuropsychopharmacology Congress.
An estimated 24 million people worldwide have schizophrenia, characterized by persistent delusions and hallucinations, according to the World Health Organization.
A prescription digital therapy has demonstrated that it can reduce the negative symptoms of schizophrenia.
Author's summary: Digital therapy may reduce schizophrenia symptoms.